Table 1.

Clinical and molecular characteristics according to p27 status in colon cancer

Clinical or molecular featureAll casesp27
P
Nuclear+ (no cytoplasmic localization)Cytoplasmic localizationLoss of expression
Total n630130330170
Sex0.004
    Male (HPFS)268 (43%)42 (32%)160 (48%)66 (39%)
    Female (NHS)362 (57%)88 (68%)170 (52%)104 (61%)
Mean age ± SD66.4 ± 8.265.9 ± 7.866.6 ± 8.766.4 ± 7.50.71
BMI (kg/m2)0.25
    <30502 (83%)107 (86%)256 (81%)139 (84%)
    ≥30104 (17%)17 (14%)60 (19%)27 (16%)
Family history of colorectal cancer in any first-degree relative0.80
    (−)467 (74%)94 (72%)248 (75%)125 (74%)
    (+)163 (26%)36 (28%)82 (25%)45 (26%)
Year of diagnosis0.24
    Before 1995276 (44%)56 (43%)154 (47%)66 (39%)
    1995 to 2002354 (56%)74 (57%)176 (53%)104 (61%)
Tumor location<0.0001
    Proximal (cecum to transverse colon)368 (59%)83 (64%)167 (51%)118 (71%)
    Distal (splenic flexure to sigmoid)254 (41%)47 (36%)158 (49%)49 (29%)
AJCC tumor stage0.44
    I127 (20%)22 (17%)74 (22%)31 (18%)
    IIA194 (31%)45 (35%)90 (27%)59 (35%)
    IIB18 (2.9%)5 (3.8%)10 (3.0%)3 (1.8%)
    IIIA21 (3.3%)8 (6.2%)9 (2.7%)4 (2.4%)
    IIIB87 (14%)13 (10%)49 (15%)25 (15%)
    IIIC54 (8.6%)9 (6.9%)33 (10%)12 (7.1%)
    IV85 (13%)18 (14%)45 (14%)22 (13%)
    Unknown44 (7.0%)10 (7.7%)20 (6.1%)14 (8.2%)
Tumor grade<0.0001
    Low556 (89%)103 (80%)314 (95%)139 (82%)
    High71 (11%)26 (20%)15 (4.6%)30 (18%)
MSI<0.0001
    MSI-low/MSS502 (81%)94 (74%)298 (92%)110 (66%)
    MSI-high114 (19%)33 (26%)25 (7.7%)56 (34%)
Mean LINE-1 methylation (%) ± SD61.0 ± 9.460.7 ± 10.361.0 ± 9.261.3 ± 9.30.74
CIMP<0.0001
    CIMP-low/0509 (81%)99 (76%)295 (89%)115 (68%)
    CIMP-high121 (19%)31 (24%)35 (11%)55 (32%)
p53 expression0.002
    (−)381 (61%)80 (63%)181 (55%)120 (71%)
    (+)245 (39%)48 (37%)148 (45%)49 (29%)
p21 (CDKN1A)<0.0001
    Expressed132 (21%)40 (32%)40 (12%)52 (31%)
    Lost485 (79%)85 (68%)283 (88%)117 (69%)
Cyclin D1 expression0.22
    (−)131 (23%)20 (17%)76 (25%)35 (23%)
    (+)444 (77%)97 (83%)228 (75%)119 (77%)
BRAF mutation<0.0001
    (−)507 (84%)97 (79%)291 (91%)119 (73%)
    (+)97 (16%)26 (21%)28 (8.8%)43 (27%)
KRAS mutation0.060
    (−)389 (63%)88 (69%)191 (59%)110 (66%)
    (+)230 (37%)39 (31%)135 (41%)56 (34%)
PIK3CA mutation0.43
    (−)449 (82%)91 (84%)234 (80%)124 (85%)
    (+)96 (18%)17 (16%)57 (20%)22 (15%)
COX-2 expression<0.0001
    (−)107 (17%)19 (15%)39 (12%)49 (29%)
    (+)521 (83%)110 (85%)290 (88%)121 (71%)
β-Catenin activation0.003
    (−)369 (67%)74 (67%)187 (62%)108 (78%)
    (+)182 (33%)37 (33%)115 (38%)30 (22%)
FASN expression0.37
    (−)535 (88%)104 (84%)284 (89%)147 (88%)
    (+)76 (12%)20 (16%)36 (11%)20 (12%)
  • NOTE: (%) indicates the proportion of tumors with a specific clinical or molecular feature in tumors with specific p27 status.

  • Abbreviations: HPFS, Health Professionals Follow-up Study; NHS, Nurses' Health Study.